Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2026—It’s hard to mount an argument against the Great Plains. Nor is there much reason to. But drive across eastern Colorado, Nebraska, Kansas, or the Dakotas, and it is a bona fide thrill to arrive in Wyoming’s northwest corner and see the Grand Tetons rising up in spectacular fashion.
April 2026—Artificial intelligence, circulating tumor DNA, trial data: ASCO 2026 next month in Chicago will feature platforms, technologies, and therapeutic approaches once considered future concepts in cancer diagnosis and care. What comes now is less flashy than a breakthrough advance perhaps, but no less significant. As Janice Lu, MD, PhD, puts it, “The real work now is disciplined clinical translation: validation, collaboration, and implementation, in ways that truly improve patient care.”
April 2026—Revisions and additions to the CAP transfusion medicine accreditation checklist released last year were made to safeguard patients, donors, and the blood bank inventory.
April 2026—Point-of-care (POC) testing for sexually transmitted infections (STIs) is crucial for combating the rising STI rates, particularly among marginalized groups.
April 2026—A new general susceptibility subsection in the microbiology checklist consolidates requirements for antibacterials, antifungals, and antimycobacterials, aiming for clarity and a broader focus beyond bacteriology.
April 2026—Laboratory and pathology billing face challenges from reimbursement threats, downcoding, denials, and prior authorizations.
April 2026—CAP TODAY publisher Bob McGonnagle spoke on Feb. 19 with Thermo Fisher Scientific’s Ravi Gupta, MBA, VP and general manager; Robert Balog, PhD, MBA, senior director, research and development; and Poulomi Acharya, PhD, senior director, global product management and market development, genetic sciences.
Bob McGonnagle: Thermo Fisher launched last fall the SwiftArrayStudio, a next-generation microarray analyzer that will support genomics research and clinical applications through the use of laboratory-validated and -developed tests. Ravi Gupta, what motivated the development of this analyzer?
Ravi Gupta: The SwiftArrayStudio resulted from listening to customers. It addresses the scientific and operational pressures observed in modern genomics. I call them the real-world needs. For decades, labs across human predictive genomics and agrigenomics have dealt with persistent challenges in workflow complexity, inconsistent turnaround times, and escalating costs. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by Thermo Fisher Scientific.
April 2026—Two new children’s books aim to introduce young readers to the world of laboratory medicine. Mia the Marvelous Lab Explorer follows a young superhero pathologist as she helps diagnose a young boy with leukemia, while ABCs of Laboratory Medicine uses the alphabet to explain various laboratory concepts.
April 2026—Pathologists are physicians who play a crucial role in patient care, providing accurate diagnoses and guiding treatment decisions. Despite often working behind the scenes, pathologists are essential to modern medicine, contributing to advancements in precision medicine and molecular diagnostics.
April 2026—Circulating metabolites, genetics, and lifestyle factors in relation to future risk of type 2 diabetes; Clinical outcomes after COVID-19–positive donor heart transplantation in a pediatric population
